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LONG TERM SURVIVAL AS A FUNCTION OF AIRWAY
OBSTRUCTION (FEV1) IN SUBJECTS WITH CHRONIC
OBSTRUCTIVE PULMONARY DISEASE: A POPULATION
BASED RECORD LINKAGE STUDY IN A LARGE UK
POPULATION
Woehl A1, Morgan CL1, Currie CJ2
1Cardiff University, Cardiff, UK, 2Department of Medicine, Cardiff, UK
OBJECTIVE: COPD increases morbidity and decreases life
expectancy. Airway obstruction as measured by the forced expi-
ratory volume in one second (FEV1) is used most commonly to
measure the extent of airways obstruction but the marginal
impact of FEV1 in decreasing survival is unclear. METHODS:
This was a retrospective record linkage study using data from a
region of Wales, UK, with a population of around 425,000
people. Data were probability matched from a number of data
sources: hospital utilisation data from local hospitals, lung func-
tion data from the Respiratory Medicine Department and mor-
tality data from the Ofﬁce of National Statistics. Individual data
sources were available spanning a period of 14 years to the
present. Survival was characterised from the ﬁrst recorded FEV1
measurement. Multivariate analysis techniques were used to
standardise for potentially confounding factors such as age, sex,
morbidity, BMI and smoking status. RESULTS: Among 33,357
subjects with data describing their FEV1 status, we identiﬁed
2,326 patients with COPD. Mean and median (SD and IQR)
FEV1 values at ﬁrst measurement were 1.04 litres and 0.89 litres
(0.64 and 1.15–2.62), respectively. Mean survival at one year
and at ﬁve years was 95.5% and 74.7%, respectively. In uni-
variate analysis by FEV1 quartile (1st quartile was the lowest
FEV1 value) survival at ﬁve years was 71.2%, 82.9%, 80.4%
and 85.0%. After standardisation for age, sex, morbidity,
smoking status and BMI using a Cox’s model, the hazard ratios
for the 1st, 2nd and 3rd quartile by comparison to the 4th were
2.3, 1.7 and 1.4, respectively. CONCLUSION: Airways obstruc-
tion (FEV1) was an important determinant of survival in COPD
following standardisation for other potentially confounding
factors.
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AN EVALUATION OF THE ASSOCIATION BETWEEN HEALTH
CARE UTILIAZATION AND USE OF SALMETEROL AMONG
SUBJECTS WITH ASTHMA
Wang MT, Malone DC, Skrepnek GH
University of Arizona,Tucson, AZ, USA
OBJECTIVE: Evaluate whether use of salmeterol increases the
risk in an asthma-related hospitalization or emergency care.
METHODS: Data for this study were extracted from the
MEDSTAT pharmacy and medical claims databases between
January 1, 2000 and December 31, 2001. A nested case-control
study design was employed to evaluate the associations of inter-
est. A cohort representing asthma patients was identiﬁed in
2000. The hospitalized cases were then identiﬁed as those with
the ﬁrst-time asthma-related hospitalization in 2001, and
matched to select controls from the study cohort by age (±5 years
of age), sex, and number of ambulatory visits for asthma (5 :1
control to case ratio). A similar selection process was used for
the asthma-related emergency department (ED) visit outcome.
The use of salmeterol was evaluated during the one-year period
before an index date for both cases and controls. Conditional
multiple logistic regressions were used to model the association
of interest. RESULTS: A total of 35,312 subjects were eligible to
be the study cohort. In addition, 284 and 640 subjects were iden-
tiﬁed as the hospitalized and ED cases, respectively. Current use
of salmeterol was associated with a 48 percent decrease in the
risk of an asthma-related hospitalization (OR = 0.52; 95% CI =
0.30 to 0.90) and a 30 percent reduction in the risk of an asthma-
related ED visit (OR = 0.697; p = 0.048). The protective effect
of salmeterol did not exist for those with recent or past use of
salmeterol. Conversely, use of seven or more canisters of salme-
terol had a decreased risk in the outcomes of interest (hospital-
ization: OR = 0.45; p < 0.001; ED visit: OR = 0.49; p < 0.001).
CONCLUSIONS: Salmeterol decreases the risk of health care
utilization if salmeterol is currently used or salmeterol is used for
seven or more canisters during a one-year period.
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COST-EFFECTIVE ANALYSIS
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PHARMACOECONOMIC EVALUATION OF SINGLE DOSE
AZITHROMYCIN EXTENDED RELEASE (AZ-ER) FOR THE
TREATMENT OF COMMUNITY-ACQUIRED PNEUMONIA 
(CAP)
Sorensen SV1, Baker TM1, Mallya UG2, Dirani RG3, Robets CS3
1Center for Health Economics and Policy, United BioSource
Corporation, Bethesda, MD, USA, 2The University of Michigan, Ann
Arbor, MI, USA, 3Pﬁzer Inc, New York, NY, USA
OBJECTIVE: To estimate the total medical costs per patient and
cost per patient cured for AZ-ER 2g single dose compared with
levoﬂoxacin 750mg for 5 days for the outpatient treatment of
mild to moderate CAP from a managed care perspective.
METHODS: A cost-effectiveness model was developed to cal-
culate the total medical costs in the ﬁrst 30 days following initial
outpatient treatment of CAP. Costs included those of initial
medical management and antibiotic therapy, treatment of
adverse events and second-line treatment, including hospitaliza-
tion. Resource use was based on the American Thoracic Society
guidelines, and unit costs were assigned based on average
Medicare RBRVS and DRG reimbursement for physician visits
and hospitalizations and Wholesale Acquisition Costs for med-
ications. Likelihood of cure and adverse events were obtained
from clinical trial data comparing AZ-ER to levoﬂoxacin. To
investigate the effect of compliance on predicted healthcare costs,
cure rates were adjusted by modeling the effects of non-compli-
ance with therapy on retreatment rates. The base case prevalence
of compliance (70%) was obtained from published sources. Sen-
sitivity analyses were conducted to determine the impact of mul-
tiple variables on outcome measures. RESULTS: Average cost per
patient was $341 in the AZ-ER group and $458 in the lev-
oﬂoxacin group. Average total cost per patient cured was $375
in the AZ-ER group and $561 in the levoﬂoxacin group. The
incremental cost-effectiveness ratio indicated dominance for AZ-
ER, having both better outcomes and a lower total cost. Com-
pliance with levoﬂoxacin and cost of levoﬂoxacin were factors
having greatest impact on cost. However, AZ-ER remained the
dominant therapy compared with levoﬂoxacin at up to 94% pre-
dicted compliance with levoﬂoxacin. CONCLUSION: Use of
AZ-ER may result in lower medical costs per person than lev-
oﬂoxacin. As non-compliance with levoﬂoxacin increases, the
difference in predicted total costs per patient between AZ-ER
and levoﬂoxacin increases.
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OBJECTIVES: To assess the cost-effectiveness of paricalcitrol IV
in the management of eligible hemodialysis (HD) patients with
secondary hyperparathyroidism (SHPT), in comparison with
standard oral vitamin D treatment. METHODS: A decision tree
model was used to estimate the cost-effectiveness of paricalcitrol
IV for HD patients with increased serum PTH levels despite stan-
dard treatment (K/DOQI guidelines). The primary perspective of
the study was that of the Dutch society in 2005. Costs and clin-
ical outcomes were discounted at 4%. The data sources included
published literature, paricalcitrol IV clinical trials, ofﬁcial
price/tariff lists and national population statistics. RESULTS:
The base case analysis from the society perspective shows that
paricalcitrol IV generates cost savings of €1714 per patient over
three years compared to standard oral vitamin D treatment
(€27,817 vs. €29,531). Paricalcitrol IV also saves 0.10 Life Years
(2.37 vs. 2.27) and leads to a gain in 0.08 QALYs (1.07 vs. 0.99).
When the analysis is performed from the health insurance per-
spective, the total cost savings reduce from €1,714 to €983, but
paricalcitrol IV remains dominant over standard oral vitamin D
treatment. Potential savings in the paricalcitrol IV treatment arm
are to be contributed to a reduction of hospitalization. Gain in
utilities is to be contributed to a decreased hospitalization rate
and increased survival of the paricalcitrol IV treated population
Sensitivity analysis showed that the outcomes were only moder-
ately sensitive to the changes in input variables for the model,
but paricalcitrol IV remained dominant in all analyses. CON-
CLUSION: This study showed that paricalcitrol IV is a cost-
saving option in the treatment of HD patients presenting SHPT
in comparison to standard oral vitamin D treatment in The
Netherlands. Introduction of paricalcitrol IV to the Dutch reim-
bursement system would propagate costs savings and a gain in
life years as well as QALYs.
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SHORT-TERM COST-EFFECTIVENESS OF RECOMBINANT
ACTIVATED FACTOR VII IN THE TREATMENT OF
INTRACEREBRAL HEMORRHAGE
Earnshaw SR1,Wilson MR1, Joshi AV2
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Novo
Nordisk Inc, Princeton, NJ, USA
Intracerebral hemorrhage (ICH) is a devastating form of stroke,
resulting in mortality and disability. A recent Phase IIb clinical
trial has shown that recombinant factor VIIa (rFVIIa, Novo-
Seven) signiﬁcantly reduces mortality in ICH patients and
improves functional outcome. OBJECTIVES: To estimate short-
term cost-effectiveness of rFVIIa compared to standard care 
in treating ICH from a US hospital (inpatient) perspective.
METHODS: A decision-analytic model was developed to esti-
mate the cost-effectiveness of rFVIIa 40mcg/kg, 80mcg/kg, and
160mcg/kg compared to standard care in treating ICH from a
hospital perspective. Costs and outcomes were estimated for a
patient’s initial hospitalization. Mortality, disability, and initial
hospital length of stay (LOS) was obtained from the Phase IIb
clinical trial. Direct medical costs for initial hospitalization fol-
lowing ICH were assumed to include all costs associated with
inpatient care estimated from an analysis of Medicare claims
data. rFVIIa costs were based on average sales price. Costs were
in 2005 US dollars. Sensitivity analyses were conducted to assess
robustness. RESULTS: Treatment with rFVIIa 40mcg/kg and
160mcg/kg resulted in additional costs of $2283 and $6700
respectively compared to standard care, which includes the cost
of rFVIIa, after factoring in relevant inpatient costs. Treatment
with rFVIIa 80mcg/kg was associated with a reduction in
expected medical costs (-$333). Given the clinical trial results,
the incremental cost-effectiveness ratio (ICER) per survivor for
rFVIIa 40mcg/kg, 80mcg/kg, and 160mcg/kg were $19,726, 
-$3178 (cost-savings), and $68,723 respectively. In addition,
average costs per survivor for rFVIIa 40mcg/kg, 80mcg/kg, 
160mcg/kg, and standard care groups were $44,102, $41,475,
$50,582 and $48,085, respectively. Results were robust to
changes in model parameters. CONCLUSIONS: Treating ICH
with rFVIIa 80mcg/kg is not only cost-effective but also cost-
saving to the hospital in the short-term compared to standard
care. Cost-effectiveness results were driven by treatment efﬁcacy
(mortality), LOS (and corresponding inpatient costs), and rFVIIa
costs.
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COST EFFECTIVENESS OF DRUG ELUTING STENTS (DES)
COMPARED TO BARE METAL STENTS (BMS) USING “REAL
WORLD” DATA
Blackhouse G, Bowen J,Tarride JE, Hopkins R, O’Reilly D,
Goeree RA
McMaster University, Hamilton, ON, Canada
OBJECTIVE: To evaluate the cost-effectiveness of DES com-
pared to BMS using outcome data derived from a cardiac patient
registry in Ontario. METHODS: A decision analytic model with
a 1 year time frame was used to estimate costs and effects
(QALYS, revascularizations) for patients receiving DES and
BMS. Prospectively collected data from the Cardiac Care
Network of Ontario patient registry was used to estimate revas-
cularization rates along with other key clinical variables to pop-
ulate the model. Stent costs were obtained from manufacturers,
while revascularizations costs (PCI, CABG) were obtained from
a hospital in southern Ontario. Utility values applied to time
with angina, post revascularization, and otherwise healthy
patients were estimated using results from the ARTS trial. Para-
meter uncertainty was assessed by means of probabilistic sensi-
tivity analysis. Cost-effectiveness was assessed on 22 unique
patient subgroups based on diabetes status, lesion characteristics
(length and diameter) and AMI within 7 days. RESULTS: Using
clinical outcome data from 7953 PCI cases, the cost-effectiveness
of DES was most favorable in non-post MI diabetes patients with
long and narrow lesions $223,000/QALY ($9869/revaculariza-
tion). This subgroup had the greatest difference in estimated 
1 year revascularization rates between BMS and DES (20.6% 
vs. 6.0%). Cost effectiveness was found to be greater than
$500,000/QALY ($20,788/revascularization) in 17 of the 22
patient cohorts (85% of patients). CONCLUSIONS: The current
analysis found that the cost-effectiveness of DES to be high in
all patient subgroups. The primary strength of the analysis is that
revascularization rates and other key model input variables were
based upon a large sample of “real world” patient data. Other
published economic analyses of drug eluting and bare metal
stents are at least partially based upon clinical trial data in which
clinical beneﬁts of DES are exaggerated compared to “real
world” practice, thus providing more favorable, but misleading,
cost-effectiveness results.
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